Kinoxis Therapeutics
Melbourne, Australia· Est.
Australian biotech leveraging ALOX15 inhibition for CNS agitation, pain, and substance‑use disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $21M
AI Company Overview
Australian biotech leveraging ALOX15 inhibition for CNS agitation, pain, and substance‑use disorders.
Central Nervous SystemPainSubstance Use Disorder
Technology Platform
Selective small‑molecule inhibition of ALOX15 to modulate neuroinflammatory lipid signaling, plus oxytocin‑receptor partial agonism for fine‑tuned neural regulation.
Opportunities
Successful Phase 2 data for KNX100 could open large dementia‑agitation markets and attract partnership or licensing deals; KNX101 addresses the growing demand for non‑opioid pain therapeutics.
Risk Factors
Clinical development risk for novel ALOX15 inhibition, reliance on external funding, and competition from other neuroinflammation‑targeting programs.
Competitive Landscape
Few companies target ALOX15 directly, giving Kinoxis a differentiated mechanism; however, it competes with established antipsychotics and emerging neuroinflammation platforms.